Clinical Trials Directory

Trials / Completed

CompletedNCT01438411

Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis

An Open Label, Single Center, Nonrandomized Continuation Study of Cholic Acid Capsules to Treat Subjects With Inborn Errors of Bile Acid Synthesis

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
53 (actual)
Sponsor
Mirum Pharmaceuticals, Inc. · Industry
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The primary purpose of the study is to evaluate the therapeutic efficacy and safety of cholic acid in subjects with identified inborn errors of bile acid synthesis.

Detailed description

This is a Phase 3, open-label, single center, nonrandomized study. This continuation protocol will consist of eligible subjects who have previously received cholic acid through the Cincinnati Children's Hospital Medical Center (CCHMC) Compassionate Use (91-10-10), CAC-001-01 study protocols and newly diagnosed subjects. New subjects will be infants, children, adolescents identified from urine samples obtained from the clinical services of programs across the U.S., Canada, South America, Europe, and Asia. Subject or their legal representative will receive information regarding the study, and the principle investigator (PI) or designee will obtain informed consent. Serum and urine samples will be collected and sent to CCHMC to measure complete bile acid profile analysis. Clinical records including medical history, physical exams, vital signs, and laboratory assessments performed as standard of care will be reviewed to ensure subject eligibility and determine baseline values. Subjects who have participated in Protocols conducted under IND 45,470 will be consented to continue to receive cholic acid capsules under this continuation protocol. Subjects will serve as their own controls and no placebo will be utilized.

Conditions

Interventions

TypeNameDescription
DRUGCholic Acid10-15 mg/kg body weight/day supplied in 50 or 250 mg Cholic Acid Capsules

Timeline

Start date
2010-01-01
Primary completion
2016-07-01
Completion
2016-07-01
First posted
2011-09-22
Last updated
2023-10-03
Results posted
2020-08-21

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01438411. Inclusion in this directory is not an endorsement.